S&P 500

5.431,60

-0,04%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Immutep Limited (PBMD)
Immutep Limited (PBMD) Notícias

PBMD

Immutep Limited (PBMD)

Immutep Limited

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:PBMD

1 2 3 4 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
23/02/2018	08:09	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:PBMD	Immutep Limited
27/11/2017	22:12	GlobeNewswire Inc.	Prima BioMed Becomes Immutep	NASDAQ:PBMD	Immutep Limited
21/11/2017	21:07	GlobeNewswire Inc.	Prima Secures European Patent Grant for Lead Product IMP321 in Cancer	NASDAQ:PBMD	Immutep Limited
20/11/2017	04:59	GlobeNewswire Inc.	Prima BioMed Changes Its Name to Immutep Ltd	NASDAQ:PBMD	Immutep Limited
15/11/2017	06:11	GlobeNewswire Inc.	Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDA	NASDAQ:PBMD	Immutep Limited
08/11/2017	20:45	GlobeNewswire Inc.	New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual...	NASDAQ:PBMD	Immutep Limited
03/11/2017	08:01	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:PBMD	Immutep Limited
31/10/2017	21:15	GlobeNewswire Inc.	Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017	NASDAQ:PBMD	Immutep Limited
20/10/2017	01:23	GlobeNewswire Inc.	Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017	NASDAQ:PBMD	Immutep Limited
19/10/2017	18:41	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-3)	NASDAQ:PBMD	Immutep Limited
19/10/2017	18:39	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:PBMD	Immutep Limited
17/10/2017	02:37	GlobeNewswire Inc.	IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting	NASDAQ:PBMD	Immutep Limited
08/09/2017	02:25	GlobeNewswire Inc.	Prima Secures Japanese Patent Grant for IMP731 Antibody	NASDAQ:PBMD	Immutep Limited
05/09/2017	04:54	GlobeNewswire Inc.	Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease	NASDAQ:PBMD	Immutep Limited
30/08/2017	07:07	GlobeNewswire Inc.	Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project	NASDAQ:PBMD	Immutep Limited
20/08/2017	21:07	GlobeNewswire Inc.	Prima BioMed Appoints Non-Executive Director to the Board	NASDAQ:PBMD	Immutep Limited
15/08/2017	23:01	GlobeNewswire Inc.	Prima BioMed Receives A $1.3 Million Tax Refund From French Government	NASDAQ:PBMD	Immutep Limited
17/07/2017	21:33	GlobeNewswire Inc.	Financial Update 2H17	NASDAQ:PBMD	Immutep Limited
16/07/2017	21:37	GlobeNewswire Inc.	Prima BioMed Announces Second Milestone Payment for IMP701 Program	NASDAQ:PBMD	Immutep Limited
14/07/2017	14:45	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	NASDAQ:PBMD	Immutep Limited
10/07/2017	00:46	GlobeNewswire Inc.	Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial	NASDAQ:PBMD	Immutep Limited
30/06/2017	18:21	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:PBMD	Immutep Limited
29/06/2017	12:39	GlobeNewswire Inc.	Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares	NASDAQ:PBMD	Immutep Limited
28/06/2017	18:22	Edgar (US Regulatory)	Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)	NASDAQ:PBMD	Immutep Limited
26/06/2017	07:33	GlobeNewswire Inc.	Operational Update	NASDAQ:PBMD	Immutep Limited
04/06/2017	21:36	GlobeNewswire Inc.	LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial	NASDAQ:PBMD	Immutep Limited
31/05/2017	21:54	GlobeNewswire Inc.	Prima BioMed Announces Formation of Clinical Advisory Board	NASDAQ:PBMD	Immutep Limited
17/05/2017	21:27	GlobeNewswire Inc.	Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference	NASDAQ:PBMD	Immutep Limited
18/04/2017	22:45	GlobeNewswire Inc.	Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial	NASDAQ:PBMD	Immutep Limited
12/04/2017	05:25	GlobeNewswire Inc.	Prima BioMed Receives A$492,144 Tax Refund From Australian Government	NASDAQ:PBMD	Immutep Limited